Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19225350 | 0.82 | SMN1; SMN2 (0.59) | RAB9ACYP3A4SMN1; SMN2 | |
| SCHEMBL8178161 | 0.77 | TSHR (0.58) | ALDH1A1TSHRAOC3NPC1RAB9A | |
| SCHEMBL30998804 | 0.77 | ALDH1A1 (0.47) | ALDH1A1TSHRAOC3NPC1RAB9A | |
| SCHEMBL1685450 | 0.74 | TSHR (0.54) | ALDH1A1TSHRAOC3NPC1RAB9A | |
| SCHEMBL8694479 | 0.74 | TAAR1 (0.45) | ALDH1A1TSHRLMNAADRA2BSLC6A2 | |
| SCHEMBL8215112 | 0.74 | TSHR (0.54) | ALDH1A1TSHRAOC3NPC1RAB9A | |
| SCHEMBL17285225 | 0.72 | TSHR (0.52) | ALDH1A1TSHRAOC3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL607788 | 0.72 | ALDH1A1 (0.52) | ALDH1A1TSHRAOC3NPC1RAB9A | |
| SCHEMBL27693295 | 0.72 | CRHBP (0.70) | ALDH1A1TSHRRAB9ANPSR1LMNA | |
| SCHEMBL1685438 | 0.71 | TSHR (0.50) | ALDH1A1TSHRAOC3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0561994-B1 | PROCESS FOR THE PREPARATION OF 2-(2-BROMO-2-NITROETHENYL)FURAN | GREAT LAKES CHEMICAL CORP (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0561994-A1 | PROCESS FOR THE PREPARATION OF 2-(2-BROMO-2-NITROETHENYL)FURAN. | GREAT LAKES CHEMICAL CORP (US) | 1993-09-29 | — | — | EP | claimed |
| US-5138076-A | Reacting furfural with primary amine in a solvent to form schiffs base, removal of sovent and water formed, dissolving intermediate in polar solvent, reacting with bromonitromethane | GREAT LAKES CHEMICAL CORPORATION (US) | 1992-08-11 | — | — | US | claimed |
| WO-1992009591-A1 | PROCESS FOR THE PREPARATION OF 2-(2-BROMO-2-NITROETHENYL)FURAN | GREAT LAKES CHEMICAL CORPORATION (US) | 1992-06-11 | — | — | WO | claimed |
| EP-1020451-B1 | ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6797717-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS | KOWA COMPANY, LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD., JAPAN | 2003-05-08 | — | — | US | disclosed |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD.,JAPAN | 2002-07-25 | — | — | US | disclosed |
| US-6362208-B1 | ANTICHOLESTEROL AGENT | KOWA COMPANY, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1020451-A1 | NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | ACAT1, ACAT2, LCAT | ALDH1A1 211/4885TSHR 4159/4885AOC3 3188/4885 |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | SOAT1, SOAT2, LCAT | ALDH1A1 236/4885TSHR 2607/4885AOC3 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.